MoneyWorks4Me

Wockhardt informs about press release

27 Jan 2026 Evaluate
Pursuant to Regulation 30 of Listing Regulations, Wockhardt has informed that it enclosed Press Release – ‘Wockhardt’s Fifth Novel Antibiotic, Foviscu® (WCK 4282), Matches Gold-Standard Meropenem in pivotal Phase 3 Trial as First-Line Therapies Fail Against Rising Resistance’. A copy of the same will also be uploaded on the Company’s website www.wockhardt.com.

The above information is a part of company’s filings submitted to BSE.
Peers
Company Name CMP
Sun Pharma. Inds. 1842.00
Dr. Reddys Labs. 1161.00
Cipla 1365.00
Lupin 2096.00
Zydus Lifesciences 1119.50
View more..